Humacyte Inc
$ 1.23
6.03%
26 Feb - close price
- Market Cap 223,876,000 USD
- Current Price $ 1.23
- High / Low $ 1.26 / 1.16
- Stock P/E N/A
- Book Value -0.03
- EPS -0.27
- Next Earning Report 2026-03-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.63 %
- ROE -2.50 %
- 52 Week High 3.50
- 52 Week Low 0.88
About
Humacyte Inc (HUMA) is a pioneering biotechnology firm dedicated to revolutionizing vascular and regenerative medicine through the development of universal human tissues. Utilizing its proprietary human acellular vessels (HAVs), the company seeks to meet critical clinical demands for vascular reconstruction and chronic disease treatment. Humacyte's innovative technology platform has the potential to produce off-the-shelf solutions that improve patient outcomes while simultaneously lowering healthcare costs. With a robust focus on regenerative medicine, Humacyte is at the forefront of advancements in transplantation and tissue engineering, poised to make significant impacts in the medical field.
Analyst Target Price
$7.71
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-11 | 2025-05-08 | 2025-03-20 | 2024-11-07 | 2024-08-13 | 2024-05-10 | 2024-03-22 | 2023-11-09 | 2023-08-14 | 2023-05-12 | 2023-03-24 |
| Reported EPS | -0.11 | -0.24 | -0.0804 | -0.2091 | -0.33 | -0.48 | -0.29 | -0.24 | -0.25 | -0.22 | -0.36 | -0.04 |
| Estimated EPS | -0.16 | -0.16 | -0.22 | -0.255 | -0.25 | -0.24 | -0.22 | -0.24 | -0.25 | -0.22 | -0.21 | -0.23 |
| Surprise | 0.05 | -0.08 | 0.1396 | 0.0459 | -0.08 | -0.24 | -0.07 | 0 | 0 | 0 | -0.15 | 0.19 |
| Surprise Percentage | 31.25% | -50% | 63.4545% | 18% | -32% | -100% | -31.8182% | 0% | 0% | 0% | -71.4286% | 82.6087% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HUMA
2026-02-19 13:27:43
D. Boral Capital has reiterated a "Buy" rating for Humacyte (NASDAQ:HUMA) with a price target of $25.00, despite the company's current unprofitability and a mixed analyst consensus of "Moderate Buy" with an average price target of $8.14. Humacyte, a clinical-stage biotech developing regenerative human acellular vessels, opened trading at $1.08, down 5.3%, with institutional investors actively modifying their holdings in the company.
2026-02-18 13:15:02
Humacyte, Inc. presented long-term safety and efficacy results for its Symvess® bioengineered human tissue in extremity arterial trauma patients at the Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society. The data showed that after up to 36 months of follow-up, Symvess maintained high rates of limb salvage, low infection rates, and no unprovoked structural failures. These results highlight Symvess's potential as a durable and effective solution for trauma patients when autologous vein grafts are not feasible.
2026-02-18 12:57:29
Humacyte, Inc. presented long-term safety and efficacy results for Symvess in extremity arterial trauma patients at the VESS Meeting. The data, spanning up to 36 months, showed high rates of limb salvage, low infection rates, and no structural failures for Symvess, highlighting its durability and potential as an alternative when autologous vein grafts are not feasible. Symvess maintained structural integrity and consistent diameter, reinforcing its benefits for severe trauma injuries.
2026-02-17 19:27:37
Humacyte Inc.'s shares saw a significant jump of 28% following news of substantial funding from the US Department of Defense for its biologic vascular repair technologies, specifically the Symvess bioengineered blood vessel product. This funding, part of the 2026 US Department of Defense Appropriations Act, has generated positive market sentiment despite the company's existing financial challenges. Analysts maintain a bullish outlook, recognizing the potential for market expansion and strategic financing to drive future growth.
2026-02-17 08:27:39
Humacyte, Inc. (NASDAQ:HUMA) has received an average "Moderate Buy" recommendation from eight analysts, with seven issuing a buy rating and one a sell rating. The average 12-month price target is set at $8.14. Shares are currently trading around $1.01, with institutional ownership nearing 44.7% following recent stake increases by major firms.
2026-02-14 11:27:49
Humacyte (HUMA) is under investor scrutiny after the U.S. Department of Defense earmarked funding for biologic vascular repair technologies, causing a significant short-term surge in its stock price. Despite a 70.46% decline over the past year, current analysis suggests Humacyte is 94.7% undervalued with a fair value of $22.83, far exceeding its current trading price of $1.22. This optimistic valuation hinges on rapid revenue expansion, a swing to profitability, and successful uptake of its ATEV in dialysis access and its coronary tissue engineered vessel in CABG.
